WORCESTER, Mass. and TORONTO, Oct. 6, 2011 /PRNewswire/ -- Generex Biotechnology Corporation's (www.generex.com) (OTCBB: GNBT) wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com), today announced that the Company will be present at the Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, October 6, 2011 at the New York Academy of Medicine in New York City. The single-day conference event unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy.
Eric von Hofe, Ph.D. President of Antigen Express, will provide an overview of the Company's lead cancer immunotherapy product candidate, AE37, at 3:00pm EDT.
A link to the live webcast will be accessible by visiting the Events and Media link under Investor Relations section of the Company's website at www.generex.com.
Pre-registration for the conference is required; no walk-ins will be accepted. To register, or for more information, please visit the conference website at www.regonline.com/mdbpartners.
Antigen Express' novel Ii-Key Hybrid Preventive HER-2/neu Peptide Vaccine (AE37) is an "off-the-shelf" cancer immunotherapy product candidate that is easier and less costly to produce than comparable cell-based approaches. AE37 is derived from a fragment of the HER2 oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER-2 expression who are not eligible for treatment with tras
|SOURCE Generex Biotechnology Corporation|
Copyright©2010 PR Newswire.
All rights reserved